In industrial societies more than 12 % of new cases of blindness are attributable to diabetes and the risk of blindness is about 30 times higher in people with diabetes than in the general population [1, 2, 3]. The WHO Multinational Study of Vascular Disease in Diabetes (WHO MSVDD), designed to compare the vascular complications of diabetes in different ethnic groups using standardised methods, included an estimate of visual function in the baseline assessment [28] . This was repeated in the follow-up study [4] , conducted at 10 of the original 14 centres, providing an opportunity to ascertain incidence and progression of visual impairment and its risk factors in these cohorts. Diabetologia (2001) Methods. Visual function was ascertained at followup in 2994 (77.9 %) of the 3845 eligible participating survivors of the 4709 originally recruited for the WHO MSVDD using the same baseline enquiry method. The associations between incident severe visual impairment, follow-up prevalence of all grades of impairment and baseline risk factors were examined by univariate and stepwise multiple logistic regression analysis. Results. Overall, 8.4 year incidence of severe visual impairment was 1.94 % and showed statistically significant univariate correlations with age at diagnosis, diabetes duration, systolic blood pressure, fasting blood glucose and cholesterol, insulin treatment and strongly with baseline retinopathy. Baseline retinopathy, systolic pressure and cholesterol were statistically significant in multivariable analysis. Differences between centres (0.3 % to 3.45 %) were not significant. Ultimate prevalence of all grades of impairment differed between centres and within almost all of them was correlated in multivariable analysis with baseline retinopathy and proteinuria. Conclusion/interpretation. Comparisons of incident severe visual impairment between centres are restricted by selective mortality, low incidence rates and relatively small numbers in each centre but before retinopathy, baseline systolic pressure and cholesterol predicted severe visual impairment. Followup prevalence of all degrees of impairment varied among centres and were associated with prior retinopathy and renal disease at baseline. [Diabetologia (2001) 
Subjects and methods
Assessment of the degree of visual impairment at follow-up was graded, as at baseline, from the responses to standard questions [5] . Of the original 4709 eligible patients in the 10 follow-up centres, 536 (11.4 %) had died, 305 (6.5 %) could not be traced and 856 failed to participate, with 3012 (77.9 % of traceable survivors) available for reassessment. This paper reports the incidence of severe visual impairment (SVI) during the follow-up period in the 2994 re-examined patients who were free of it at baseline. It also reports the prevalence of mild, moderate and severe visual disability present in all 3012 patients at re-examination and explores the association of baseline risk factors [4] with these findings.
Statistical analysis. Statistical analysis was done using SAS software (Carey, N. C., USA) [7] . Univariate analyses included chisquare statistic and Student's t test. The rate ratios and 95 % confidence intervals for incidence of severe visual impairment were estimated by baseline variables [8] using the MantelHaenszel test for bivariate analyses [9] and stepwise linear logistic regression for multivariate analyses [10] . A p value of less than 0.05 was considered statistically significant.
Results
Incidence of severe visual impairment. Among the 3 868 traceable patients alive at follow-up, 23 (0.59 %) had SVI at baseline. Follow-up information was available for 2994 (77.9 %) of the rest and 851 (22.1 %) were lost to follow-up.
Severe visual impairment had developed in 58 patients, an incidence of 1.94 % (Table 1) . Proliferative diabetic retinopathy alone led to SVI in 21 (36.2 %), cataract alone in 10 (17.2 %), and both conditions in 9 (15.5 %). In 18 patients SVI was the consequence of diabetic maculopathy, in some associated with proliferative retinopathy, cataract, glaucoma or corneal opacity, and maculopathy probably contributed in others. Reported incidence of SVI was high in Zagreb (3.45 %), Arizona (3.43 %) and Havana (2.97 %) and low in Berlin (0.30 %) but differences between centres were not significant.
Incidence of SVI by centre and type of diabetes is shown in Figure 1 . Differences in incidence between patients with Type I (insulin-dependent) diabetes mellitus and those with Type II (non-insulin-dependent) diabetes mellitus failed to achieve statistical significance in individual centres and in all centres (excluding Arizona where there were no patients with Type I diabetes) combined.
Because numbers at individual centres were small, univariate analysis of the relation between baseline variables and incident SVI was done using pooled data from all 10 centres, except for baseline fasting glucose concentrations for which 8 centres were pooled. Baseline factors associated with SVI (Table 2) included age at diagnosis, duration of diabetes, systolic blood pressure, fasting plasma glucose and cholesterol, type of treatment and baseline retinopathy (Fig. 2) . No significant associations were found with sex, age, type of diabetes, diastolic blood pressure, BMI, smoking status, fasting triglycerides, renal disease or macrovascular disease at baseline.
Stepwise linear logistic regression analysis on the pooled data ( Stepwise linear logistic regression analysis in the 8 centres with adequate numbers with any visual impairment included baseline variables: sex, age, duration of diabetes, hypertension status, BMI, current smoking status, insulin use, fasting plasma glucose, and any retinopathy, renal disease and macrovascular disease. Baseline retinopathy and renal disease were significantly associated in almost all centres (Table 4) but other factors were less universally related. Current smoking was not significant at any centre.
Discussion
Diabetes remains a leading cause of blindness and lesser visual impairment in working-aged adults, particularly in industrial societies. In the United States it was estimated that 12 % of all new blindness was attributable to diabetic retinopathy [1] , a proportion comparable to that reported from analysis of blindness registrations in the United Kingdom [11, 12] . In these societies adults with diabetes are at a 25 to 30 times greater risk of blindness than the general adult population. There is a number of reports on prevalence and incidence of visual impairment in diabetes [1, 11±28] but there are no multinational comparisons. A comprehensive review of diabetes and its complications [13] , retrieved from the world literature, provided data on the varying estimates of prevalence of retinopathy but did not include visual disability.
The subjective measures of visual dysfunction reported here were selected as suitable for the wide range of centres collaborating in this study but were inevitably influenced by observer variation and bias. These findings can thus be presented only as a broad representation of the changing visual status of the multinational cohorts reported. The baseline prevalence of SVI in the patients originally constituting the 10 follow-up centres was 0.89 % [28] . During the E. Miki et al.: Visual impairment and its determinants S 34 follow-up, 1.94 % of those free of SVI at baseline entered this category, raising the overall prevalence (p < 0.001) to 2.25 %. This is likely to be a substantial underestimate of the true incidence, however. Others have described the greatly increased mortality risk of those with visual impairment [29, 30] . Of the 42 with SVI at baseline in this study, 19 (45.2 %) had died by the time of follow-up compared with 536 (11.4 %) of the original cohort of 4709. Many of the other 517 decedents could have become seriously visually impaired by the time of death; at baseline they had longer duration of diabetes, higher systolic blood pressures and higher plasma cholesterol than the survivors, all risk factors for SVI. The 851 non-participating survivors (22.1 % of the cohort) also had longer diabetes duration and higher arterial pressures at baseline than the participants. The cumulative SVI incidence of 1.94 % over a mean of 8.4 years is lower than that reported over 4 years in the older onset group of the Wisconsin (WESDR) study [15] , namely 3.2 % and 2.7 % for those taking insulin and those not taking insulin respectively. The annual incidence of blindness fell substantially in the subsequent 6 years of this study. Our criteria of SVI were probably more rigorous than those of WESDR (VA of 20/200 or less in the better eye).
The variation in incidence of SVI among WHO MSVDD centres was not significant and was comparable with the variation among other published incidence rates [11,12,14±22,25±27] . Its distribution was, however, broadly consistent with the relative incidence of ophthalmoscopically ascertained retinopathy among them [4] . Prevalence rates of any visual impairment at follow-up were higher and differences between centres significant (p < 0.01).
Retinopathy at baseline was a highly significant predictor of SVI, a correlation well documented elsewhere [15±21, 27, 32, 33] . Patients with baseline nonproliferative retinopathy were 3 times more likely to develop SVI and those with proliferative retinopathy 16 times, than those free of retinopathy at baseline. Systolic blood pressure, associated with baseline retinopathy [28, 34] and retinopathy progression [6] , was also a powerful independent predictor of SVI. The relation between arterial pressure, retinopathy and the potential for visual impairment has been noted in many other studies [22, 31, 35, 36] . Most recently, tight control of raised blood pressure in Type II diabetes has been shown to slow the progression of retinopathy and reduce the need for photocoagulation compared with less tight pressure control [41] . Renal disease, strongly associated with retinopathy and increased arterial pressure could contribute to the association of SVI with baseline blood cholesterol, significant in both univariate and multivariate analyses and reported elsewhere [23, 24, 27] .
As in other reports [14, 17, 25±27] , age at diagnosis and diabetes duration were also found to be significant univariate predictors of visual impairment. Estimates of diabetes duration are not likely to be reliable in patients with Type II diabetes. This along with the increasing role of non-diabetic eye disease in older people makes it difficult to interpret differences in visual impairment between Type I and Type II diabetes. In this study, women had a higher prevalence of visual impairment than men in London and Tokyo present after adjusting for other risk factors and an increased risk of diabetic blindness in women has been noted in some earlier studies [17, 25, 26] .
Patients treated with insulin were at greater risk for incident SVI in univariate analysis of pooled data (Table 2 ) and, by multivariate analysis, for any visual impairment in the Tokyo and Oklahoma cohorts [15, 19, 20] . Insulin use is, however, a marker for more severe degrees of hyperglycaemia. Furthermore, in some centres, visual disorder could be an indication for starting insulin treatment. In the 8 centres where baseline fasting glucose was measured, incident SVI was twice as high in those in the top third of the glucose distribution as in the lower two thirds. The importance of hyperglycaemia in the incidence of retinopathy and the progression of mild to moderate retinopathy was highlighted by DCCT [38] though its late stages are likely to be increasingly influenced by other determinants [39, 40] particularly by the retinovascular damage itself.
